In this ASCO-GI research special, Dr. Bekaii-Saab of Mayo Clinic provides an insightful and comprehensive roundup of the most groundbreaking studies unveiled at the ASCO GI 2024 meeting.
He joins me on Healthcare unfiltered to Delve into the realm of hepato-cellular carcinoma, he dissects the pivotal previously-reported data from IMbrave050 and ASCO GI findings from EMERALD-1. Then, he sheds light on developments in colorectal cancer, exploring the impact of KEYNOTE-177 and CheckMate 8HW. Moreover, Dr. Bekaii-Saab explores the latest advancements in minimal residual disease assessment with a focus on studies like BESPOKE and GALAXY, as well as the prognostic value of ctDNA assessment showcased in COBRA
N/A
Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding
Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary
In this special episode, I give up the microphone to guest host Kelly Ryerson, who takes over the show asking questions about my new book “The Cancer Journey.”
